EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access

Integrated care van delivery of evidence‐based services for people who inject drugs: A cluster‐randomized trial

Kathleen R Page, Brian W Weir, Katie Zook, Amanda Rosecrans, Robert Harris, Suzanne M Grieb, Oluwaseun Falade-Nwulia, Miles Landry, Wendy Escobar, Michael P Ramirez, Ronald E Saxton, William A Clarke and 2 more

Addiction · 2024

DOI: 10.1111/add.16486 ↗

At a glance

Randomisierte kontrollierte Studie in Addiction, 2024. Written by Kathleen R Page and 13 co-authors. Institution: Johns Hopkins University School of Medicine, Baltimore, MD, USA. Major MEDLINE topics: Substance Abuse, Intravenous, Needle-Exchange Programs. Cited 5 times so far (Crossref); 23 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, NIAID NIH HHS, NINR NIH HHS.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and aims People who inject drugs (PWID) are at risk for adverse outcomes across multiple dimensions. While evidence‐based interventions are available, services are often fragmented and difficult to access. We measured the effectiveness of an integrated care van (ICV) that offered services for PWID. Design, setting and participants This was a cluster‐randomized trial, which took place in Baltimore, MD, USA. Prior to randomization, we used a research van to recruit PWID cohorts from 12 Baltimore neighborhoods (sites), currently served by the city's mobile needle exchange program. Intervention and comparator We randomized sites to receive weekly visits from the ICV ( n = 6) or to usual services ( n = 6) for 14 months. The ICV offered case management; buprenorphine/naloxone; screening for HIV, hepatitis C virus and sexually transmitted infections; HIV pre‐exposure prophylaxis; and wound care.

Measurements

The primary outcome was a composite harm mitigation score that captured access to evidence‐based services, risk behaviors and adverse health events (range = 0−15, with higher numbers indicating worse status). We evaluated effectiveness by comparing changes in the composite score at 7 months versus baseline in the two study arms.

Findings

We enrolled 720 cohort participants across the study sites (60 per site) between June 2018 and August 2019: 38.3% women, 72.6% black and 85.1% urine drug test positive for fentanyl. Over a median of 10.4 months, the ICV provided services to 734 unique clients (who may or may not have been cohort participants) across the six intervention sites, including HIV/hepatitis C virus testing in 577 (78.6%) and buprenorphine/naloxone initiation in 540 (74%). However, only 52 (7.2%) of cohort participants received services on the ICV. The average composite score decreased at 7 months relative to baseline, with no significant difference in the change between ICV and usual services (difference in differences: −0.31; 95% confidence interval: −0.70, 0.08; P = 0.13).

Conclusions

This cluster‐randomized trial in Baltimore, MD, USA, found no evidence that weekly neighborhood visits from a mobile health van providing injection‐drug‐focused services improved access to services and outcomes among people who injected drugs in the neighborhood, relative to usual services. The van successfully served large numbers of clients but unexpectedly low use of the van by cohort participants limited the ability to detect meaningful differences.

Subjects

MeSH terms (MEDLINE)

Substance Abuse, IntravenousNeedle-Exchange ProgramsHumansFemaleMaleAdultBaltimoreHIV InfectionsMiddle AgedDelivery of Health Care, IntegratedBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsHarm ReductionMobile Health UnitsHepatitis CEvidence-Based Practice

Author keywords

BuprenorphineHCVHIVharm reductionopioid use disorderpeople who inject drugsservice delivery

Substances

Buprenorphine, Naloxone Drug CombinationNarcotic Antagonists

Authors and institutions

  • Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Baltimore City Health Department, Baltimore, MD, USA.

ORCID profiles: Gregory M Lucas

Funding

  • NIDA NIH HHS
  • NIAID NIH HHS
  • NINR NIH HHS
  • The Johns Hopkins University Center for AIDS Research
  • National Institute on Drug Abuse

Cite

APA

Page, K. R., Weir, B. W., Zook, K., Rosecrans, A., Harris, R., Grieb, S. M., Falade-Nwulia, O., Landry, M., Escobar, W., Ramirez, M. P., Saxton, R. E., Clarke, W. A., Sherman, S. G., & Lucas, G. M. (2024). Integrated care van delivery of evidence‐based services for people who inject drugs: A cluster‐randomized trial. Addiction. https://doi.org/10.1111/add.16486

Vancouver

Page KR, Weir BW, Zook K, Rosecrans A, Harris R, Grieb SM, et al. Integrated care van delivery of evidence‐based services for people who inject drugs: A cluster‐randomized trial. Addiction. 2024. doi:10.1111/add.16486

BibTeX
@article{Page2024,
  author = {Page, Kathleen R and Weir, Brian W and Zook, Katie and Rosecrans, Amanda and Harris, Robert and Grieb, Suzanne M and Falade-Nwulia, Oluwaseun and Landry, Miles and Escobar, Wendy and Ramirez, Michael P and Saxton, Ronald E and Clarke, William A and Sherman, Susan G and Lucas, Gregory M},
  title = {Integrated care van delivery of evidence‐based services for people who inject drugs: A cluster‐randomized trial},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16486}
}
Start for free →